Molecular immunological mechanism of abnormal activated T cell in systemic lupus erythematosus

Abstract

Abstract: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease, whose pathogenesis is very complicated. T cells contribute to the initiation and perpetuation of autoimmunity in SLE, and seem to be directly involved in the development of related organ pathology. Abnormal T cell activation could result in cytokine imbalance,the persistence of auto-reactive T cells, increased T cells apoptosis, these changes play pivotal role in SLE pathogenesis. This article presents an overview of the current research of abnormal T cell activation in SLE, include disorder of cell membrane signal, intracellular kinase, and transcription factor,and their effect on the occur and development of SLE.

Key words: Systemic lupus erythematosus, T cell, T cell activation

CLC Number:

R593.24⁺1

ZHAO Hai-hui, ZHAO Yin-huan. Molecular immunological mechanism of abnormal activated T cell in systemic lupus erythematosus[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(4): 452-457.

References

[1] Mageed RA, Prud'homme GJ. Immunopathology and the gene therapy of lupus[J].Gene Ther, 2003, 10(10): 861-874.
[2] Herrmann M,Winkler T,Gaipl U,et al. Etiopathogenesis of systemic lupus erythematosus[J].Int Arch Allergy Immunol,2000,123(1):28-35.
[3] Riemekasten G,Hahn BH.Key autoatigens in SLE[J]. Rheumatology,2005,44(8):975-982.
[4] José CC, Vasileios CK, Cox T, et al. T cell as therapeutic target in SLE[J]. Nat Rev Rheumatol, 2010,6:317-325.
[5] Januchowski R,Wudarski M,Jagodzinski PP,et al.Prevalence of ZAP-70,LAT,SLP-76,and DNA methyltransferase 1 expression in CD4+ T cells of patients with systemic lupus erythematosus[J].Clin Rheumatol,2008,27(1):21-27.
[6] Nel AE.T-cell activation through the antigen receptor.Part1:signaling components,signaling pathways,and signal integration at the T-cell antigen receptor synapse[J].Clin Immunol,2002,109(5):758-770.
[7] Krishnan S,Nambiar MP,Warke VG,et al.Alterations in lipid raft composition and dynmics contribute to abnormal T cell responses in systemic lupus erythematosus[J].J Immunol,2004,172(12):7821-7831.
[8] Deng GM,Tsokos GC.Cholera toxin B accelerates disease progression in lupus-prone mice by promoting lipid raft aggregation[J].J Immunol,2008,181(6):4019-4026.
[9] Jury EC,Isenberg DA,Mauri C,et al.Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus[J].J Immunol, 2006, 177(10): 7416-7422.
[10] Fernandez D,Perl A.Metabolic control of T-cell activation and death in SLE[J].Autoimmun Rev,2009,8(3):184-189.
[11] Jury EC,Kabouridis PS,Abba A,et al.Increased ubiquitination and reduced expression of LCK in T lymphocytes from patients with systemic lupus erythematosus[J].Arthritis Rheum,2003,48(5):1343-1354.
[12] Tenbrock K,Juang YT,Kyttaris VC,et al.Altered signal transduction in SLE T cells[J].Rheumatology,2007,46(10):1525-1530.
[13] Kozlowska A,Hrycai P,Lacki JK,et al.Fyn and CD70 expression in CD4+ T cells from patients with systemic lupus erythematosus[J].J Rheumatol,2010,37(1):53-59.
[14] Krishnan S,Juang YT,Chowdhury B, et al.Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells[J].J Immunol,2008,181(11):8145-8152.
[15] Yoshimoto K,Setoyama Y,Tsuzaka K,et al.Reduced expression of TCR zeta is involved in the abnormal production of cytokines by peripheral T cells of patients with systemic lupus erythematosus[J]. J Biomed Biotechnol,2010,2010,pii:509021.
[16] Jury EC,Flores-Borja F,Kalsi HS,et al.Abnormal CTLA-4 function in T cells from patients with systemic lupus erythematosus[J].Eur J Immunol,2010,40(2):569-578.
[17] 余文胜,吴昊,汤正好,等.CTLA-4 siRNA对慢性乙型肝炎患者外周血Th1/Th2细胞因子的影响[J].中国临床药理学与治疗学,2011,16(5):553-558.
[18] Mihara M, Tan I, Chuzhin Y,et al .CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus[J].J Clin Invest,2000,106(1):91-101.
[19] Daikh DI,Wofsy D.Cutting Edge:Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide[J].J Immunol,2001,166(5):2913-2916.
[20] Fernandez D,Bonilla E,Phillips P,et al.Signaling abnormalities in systemic lupus erythematosus as potential drug targets[J].Endocr Metab Immune Disord Drug Targets,2006,6(4):305-311.
[21] Braselmann S,Taylor V,Zhao H,et al.R406,an orally available spleen tyrosine kinase inhibitor blocks fc receptorsignaling and reduces immune complex-mediated inflammation[J].J Pharmacol Exp Ther,2006,319(3):998-1008.
[22] Noraz N,Schwarz K,Steinberg MD,et al.Alternative antigen receptor (TCR) signaling in T cells derived from ZAP-70-deficient patients expressing high levels of Syk[J].J Biol Chem,2000,275(21):15832-15838.
[23] Lieberman LA,Tsokos GC.The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity[J].J Biomed Biotechnol,2010,2010:740619.
[24] 朱琳,华之卉,宋洪涛.他克莫司的药物基因组学与个体化用药[J].中国临床药理学与治疗学,2011,16(6):710-715.
[25] Kyttaris VC,Zhang Z,Kampaqianni O,et al.Calcium signaling in systemic lupus erythematosus T cells: a treatment target[J].Arthritis Rheum,2011,63(7):2058-2066.
[26] Katsiari CG,Kyttaris VC,Juang YT,et al.Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus[J].J Clin Invest,2005,115(11):3193-3204.
[27] Kyttaris VC,Juang YT,Tenbrock K,et al.Cyclic adenosine 5'-monophosphate response element modulator is responsible for the decreased expression of c-fos and activator protein-1 binding in T cells from patients with systemic lupus erythematosus[J].J Immunol,2004,173(5):3557-3563.
[28] Sidiropoulos PI,Boumpas DT.Lessons learned from anti-CD₄₀L treatment in systemic lupus erythematosus patients[J].Lupus,2004,13(5):391-397.
[29] Boumpas DT,Furie R,Manzi S,et al.A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis[J].Arthritis Rheum,2003,48(3):719-727.
[30] Fujii Y, Fujii K, Tanaka Y. Attempt to correct abnormal signal transduction in T lymphocytes from systemic lupus erythematosus patients[J]. Autoimmun Rev,2006,5(2):143-144.
[31] Horiuchi T,Himeji D,Tsukamoto H,et al.Dominant expression of a novel splice variant of caspase-8 in human peripheral blood lymphocytes[J].Biochem Biophys Res Commun,2000,272(3):877-881.
[32] Herndon TM,Juang YT,Solomou EE,et al.Direct transfer of p65 into T lymphocytes from systemic lupus erythematosus patients leads to increased levels of interleukin-2 promoter activity[J].Clin Immunol,2002,103(2):145-153.
[33] Tenbrock K,Juang YT,Gourley MF,et al.Antisense cyclic adenosine 5'-monophosphate response element modulator up-regulates IL-2 in T cells from patients with systemic lupus erythematosus[J].J Immunol,2002,169(8):4147-4152.